Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.

Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).

His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
361 entries « 1 of 37 »

Dubuis ME, Degois J, Veillette M, Turgeon N, Paquet-Bolduc B, Boivin G, Duchaine C

High and low flowrate sampling of airborne influenza in hospital rooms during three outbreaks

Journal Article

J Aerosol Sci, 158 , 2021.

| Links:

Chupin C, Pizzorno A, Traversier A, Brun P, Ogonczyk-Makowska D, Padey B, Milesi C, Dulière V, Laurent E, Julien T, Galloux M, Lina B, Eléouët JF, Moreau K, Hamelin ME, Terrier O, Boivin G, Dubois J, Rosa-Calatrava M

Avian Cell Line DuckCelt-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac.

Journal Article

Vaccines (Basel), 9 (10), 2021.

Abstract | Links:

Mhamdi Z, Carbonneau J, Venable MC, Baz M, Abed Y, Boivin G

Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.

Journal Article

J Gen Virol, 102 (10), 2021.

Abstract | Links:

Uyar O, Plante PL, Piret J, Venable MC, Carbonneau J, Corbeil J, Boivin G

A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis.

Journal Article

Sci Rep, 11 (1), 2021.

Abstract | Links:

Prévost J, Richard J, Gasser R, Ding S, Fage C, Anand SP, Adam D, Tauzin A, Benlarbi M, Gong SY, Goyette G, Privé A, Moreira S, Charest H, Roger M, Mothes W, Pazgier M, Brochiero E, Boivin G, Abrams CF, Schön A, Finzi A, Gupta Vergara N

Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2.

Journal Article

J Biol Chem, 297 (4), 2021.

Abstract | Links:

Niesor EJ, Boivin G, Rhéaume E, Shi R, Lavoie V, Goyette N, Picard ME, Perez A, Laghrissi-Thode F, Tardif JC

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib.

Journal Article

ACS Omega, 6 (25), 2021.

Abstract | Links:

Zinszer K, McKinnon B, Bourque N, Zahreddine M, Charland K, Papenburg J, Fortin G, Hamelin MÈ, Saucier A, Apostolatos A, Pierce L, Savard-Lamothe A, Carbonneau J, Conrod P, Haley N, Laurin I, Boivin G, De Serres G, Quach C

Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada.

Journal Article

BMJ Open, 11 (7), 2021.

Abstract | Links:

Dubuis ME, Racine É, Vyskocil JM, Turgeon N, Tremblay C, Mukawera E, Boivin G, Grandvaux N, Duchaine C

Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes.

Journal Article

PLoS One, 16 (7), 2021.

Abstract | Links:

Piret J, Boivin G

Antiviral Drugs Against Herpesviruses.

Journal Article

Adv Exp Med Biol, 1322 , 2021.

Abstract | Links:

Prévost J, Richard J, Gasser R, Ding S, Fage C, Anand SP, Adam D, Vergara NG, Tauzin A, Benlarbi M, Gong SY, Goyette G, Privé A, Moreira S, Charest H, Roger M, Mothes W, Pazgier M, Brochiero E, Boivin G, Abrams CF, Schön A, Finzi A

Impact of temperature on the affinity of SARS-CoV-2 Spike for ACE2.

Journal Article

bioRxiv, 2021.

Abstract | Links:

361 entries « 1 of 37 »
Signaler des ajouts ou des modifications

Active projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, from 2016-07-01 to 2023-06-30
  • Canadian Immunization Research Network, from 2014-06-01 to 2021-12-31
  • Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE), from 2020-11-01 to 2022-09-30
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, from 2018-10-01 to 2022-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2022-02-28
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2023-03-31
  • Plateforme de laboratoire de niveau de confinement 3 respiratoire, from 2020-03-25 to 2022-03-27
  • Projet du Groupe québécois de recherche sur l'infection périnatale à COVID-19 (Banque de données des grossesses COVID-19), from 2020-04-01 to 2022-03-31

Recently finished projects

  • Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, from 2013-07-01 to 2020-06-30
  • COVID-19 household study to assess secondary attack rates and the proportion asymptomatic, including children, from 2020-06-01 to 2021-05-31
  • REinfection in COVid-19 Estimation of Risk (RECOVER), from 2020-06-01 to 2020-09-30
  • Seeking for innovative approaches in prevention and cure to COVID-19 disease, from 2020-11-01 to 2021-08-30
  • Sentinel surveillance, viral shedding, clinical characteristics and outcomes of confirmed and suspected hospitalized cases of COVID-19/SARS-CoV-2 infection in the Canadian Immunization Research Network (CIRN), from 2020-04-01 to 2021-09-30
  • Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus, from 2020-05-01 to 2021-03-31
Data provided by the Université Laval research projects registery